Valeant (VRX) Stock Higher, FDA Panel Backs Psoriasis Drug

Valeant (VRX) stock is advancing as an FDA advisory panel backed its psoriasis drug with risk management measures.
By Kaya Yurieff ,

NEW YORK (TheStreet) -- Shares of Valeant Pharmaceuticals Int'l (VRX) are up 1.06% to $23.75 as its experimental drug to treat psoriasis should be approved as long as certain measures to mitigate the risk of suicide are put into place, an advisory committee to the FDA concluded today, Reuters reports.

The FDA does not have to follow the advice of its advisory committees but it usually does.

Psoriasis is a condition in which skin cells build up and form scales and itchy, dry patches.

Separately, TheStreet Ratings Team has a "Sell" rating with a score of D on the stock.

The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

You can view the full analysis from the report here: VRX

Loading ...